Amyloid-β contributes to blood-brain barrier leakage in transgenic human amyloid precursor protein mice and in humans with cerebral amyloid angiopathy

Stroke

Volumn 43, Issue 2, 2012, Pages 514-523

  Hartz, Anika M S ^a   Bauer, Björn ^a   Soldner, Emma L B ^a   Wolf, Andrea ^a   Boy, Sandra ^b   Backhaus, Roland ^b   Mihaljevic, Ivan ^b   Bogdahn, Ulrich ^b   Klünemann, Hans H ^b   Schuierer, Gerhard ^b   Schlachetzki, Felix ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

amyloid ; blood brain barrier; cerebral amyloid angiopathy; neuroimaging

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CLAUDIN 1; CLAUDIN 5; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN MICROCIRCULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HEMOSIDEROSIS; HUMAN; HUMAN CELL; MALE; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIGHT JUNCTION; TRANSGENIC MOUSE; TREATMENT RESPONSE; VASCULAR AMYLOIDOSIS; WHITE MATTER; WILD TYPE;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; APOLIPOPROTEINS E; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; CAPILLARIES; CELL MEMBRANE; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL HEMORRHAGE; FEMALE; FLUORESCENT DYES; HEMOSIDEROSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASES; MICE; MICE, TRANSGENIC; MIDDLE AGED; PATIENT SELECTION; PHENOTYPE; STROKE; TIGHT JUNCTIONS; TOMOGRAPHY, X-RAY COMPUTED; XANTHENES;

EID: 84856429045     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.627562     Document Type: Article

References (54)

1. Love S, Miners S, Palmer J, Chalmers K, Kehoe P. Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy. Front Biosci. 2009;14:4778-4792.
2. Maia LF, Mackenzie IR, Feldman HH. Clinical phenotypes of cerebral amyloid angiopathy. J Neurol Sci. 2007;257:23-30. (Pubitemid 46856515)
3. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653-660. (Pubitemid 36578587)
4. Chow N, Bell RD, Deane R, Streb JW, Chen J, Brooks A, et al. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci USA. 2007;104:823-828. (Pubitemid 46154695)
5. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56:537-539. (Pubitemid 32172884)
6. Kofler J, Bartynski WS, Reynolds TQ, Lieberman FS, Murdoch GH, Hamilton RL. Posterior reversible encephalopathy syndrome (PRES) with immune system activation, VEGF up-regulation, and cerebral amyloid angiopathy. J Comput Assist Tomogr. 2011;35:39-42.
7. Menon RS, Kidwell CS. Neuroimaging demonstration of evolving small vessel ischemic injury in cerebral amyloid angiopathy. Stroke. 2009;40: e675-e677.
8. Raposo N, Viguier A, Cuvinciuc V, Calviere L, Cognard C, Bonneville F, et al. Cortical subarachnoid haemorrhage in the elderly: A recurrent event probably related to cerebral amyloid angiopathy. Eur J Neurol. 2011;18: 597-603.
9. Chung KK, Anderson NE, Hutchinson D, Synek B, Barber PA. Cerebral amyloid angiopathy related inflammation: three case reports and a review. J Neurol Neurosurg Psychiatry. 2011;82:20-26.
10. Zipfel GJ, Han H, Ford AL, Lee JM. Cerebral amyloid angiopathy: progressive disruption of the neurovascular unit. Stroke. 2009;40: S16-S19.
11. Gonzalez-Velasquez FJ, Kotarek JA, Moss MA. Soluble aggregates of the amyloid-beta protein selectively stimulate permeability in human brain microvascular endothelial monolayers. J Neurochem. 2008;107: 466-477.
12. Han BH, Zhou ML, Abousaleh F, Brendza RP, Dietrich HH, Koenigsknecht-Talboo J, et al. Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid-beta peptide, partial restoration via gamma-secretase inhibition. J Neurosci. 2008;28:13542-13550.
13. Christie R, Yamada M, Moskowitz M, Hyman B. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol. 2001;158:1065-1071. (Pubitemid 32221798)
14. Hartz AM, Miller DS, Bauer B. Restoring blood-brain barrier p-glycoprotein reduces brain amyloid-beta in a mouse model of Alzheimer's disease. Mol Pharmacol. 2010;77:715-723.
15. Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS. Coordinated nuclear receptor regulation of the efflux transporter, MRP2, and the phase-II metabolizing enzyme, GSTPI, at the blood-brain barrier. J Cereb Blood Flow Metab. 2008;28:1222-1234. (Pubitemid 351733346)
16. Hartz AM, Bauer B, Block ML, Hong JS, Miller DS. Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and p-glycoprotein up-regulation at the blood-brain barrier. Faseb J. 2008;22: 2723-2733.
17. Hartz AM, Bauer B, Fricker G, Miller DS. Rapid regulation of p-glycoprotein at the blood-brain barrier by endothelin-1. Mol Pharmacol. 2004; 66:387-394. (Pubitemid 39329237)
18. Fazekas F, Kleinert R, Offenbacher H, Schmidt R, Kleinert G, Payer F, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology. 1993;43:1683-1689. (Pubitemid 23307935)
19. Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, et al. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology. 2010;75:160-167.
20. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102. (Pubitemid 26332733)
21. Marco S, Skaper SD. Amyloid beta-peptide 1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci Lett. 2006;401:219-224. (Pubitemid 44250979)
22. Tai LM, Holloway KA, Male DK, Loughlin AJ, Romero IA. Amyloidbeta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med. 2010;14:1101-1112.
23. Carrano A, Hoozemans JJ, van der Vies SM, Rozemuller AJ, van Horssen J, de Vries HE. Amyloid beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy. Antioxid Redox Signal. 2011;15:1167-1178.
24. Gravina SA, Ho L, Eckman CB, Long KE, Otvos L, Jr., Younkin LH, et al. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at a beta 40 or a beta 42(43). J Biol Chem. 1995;270: 7013-7016.
25. Han F, Ali Raie A, Shioda N, Qin ZH, Fukunaga K. Accumulation of beta-amyloid in the brain microvessels accompanies increased hyperphosphorylated tau proteins following microsphere embolism in aged rats. Neuroscience. 2008;153:414-427.
26. Lee JM, Yin K, Hsin I, Chen S, Fryer JD, Holtzman DM, et al. Matrix metalloproteinase-9 in cerebral-amyloid-angiopathy-related hemorrhage. J Neurol Sci. 2005;229-230:249-254. (Pubitemid 40341590)
27. Tanskanen M, Myllykangas L, Saarialho-Kere U, Paetau A. Matrix metalloproteinase-beta 19 expressed in cerebral amyloid angiopathy. Amyloid. 2011;18:3-9.
28. Utter S, Tamboli IY, Walter J, Upadhaya AR, Birkenmeier G, Pietrzik CU, et al. Cerebral small vessel disease-induced apolipoprotein e leakage is associated with Alzheimer disease and the accumulation of amyloid beta-protein in perivascular astrocytes. J Neuropathol Exp Neurol. 2008; 67:842-856.
29. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG, et al. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol. 2010;69: 1034-1043.
30. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer's amyloid-SS(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489-1499. (Pubitemid 32038587)
31. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333-344. (Pubitemid 39061126)
32. Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke. 2004;35:2628-2631. (Pubitemid 39458354)
33. Bell RD, Deane R, Chow N, Long X, Sagare A, Singh I, et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol. 2009;11:143-153.
34. Murozono M, Matsumoto S, Okada S, Nagaoka D, Isshiki A, Watanabe Y. Reduction of brain infarction induced by a transient brain ischemia in mdr1a knockout mice. Neurochem Res. 2009;34:1555-1561.
35. Miller DS, Bauer B, Hartz AM. Modulation of p-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60:196-209. (Pubitemid 351962009)
36. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005;115:3285-3290. (Pubitemid 41567593)
37. Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, et al. The role of p-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2004;1:121-125.
38. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061-2070.
39. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178-201.
40. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol. 2009;8:205-216.
41. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319. (Pubitemid 38269583)
42. Greenberg SM, Grabowski T, Gurol ME, Skehan ME, Nandigam RN, Becker JA, et al. Detection of isolated cerebrovascular beta-amyloid with Pittsburgh Compound B. Ann Neurol. 2008;64:587-591.
43. Cuvinciuc V, Viguier A, Calviere L, Raposo N, Larrue V, Cognard C, et al. Isolated acute nontraumatic cortical subarachnoid hemorrhage. AJNR Am J Neuroradiol. 2010;31:1355-1362.
44. Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood). 2005;230:118-127.
45. Bernstein RA, Gibbs M, Hunt Batjer H. Clinical diagnosis and successful treatment of inflammatory cerebral amyloid angiopathy. Neurocrit Care. 2011;14:453-455.
46. Pirker A, Kramer L, Voller B, Loader B, Auff E, Prayer D. Type of edema in posterior reversible encephalopathy syndrome depends on serum albumin levels: An MR imaging study in 28 patients. AJNR Am J Neuroradiol. 2011;32:527-531.
47. Hefzy HM, Bartynski WS, Boardman JF, Lacomis D. Hemorrhage in posterior reversible encephalopathy syndrome: imaging and clinical features. AJNR Am J Neuroradiol. 2009;30:1371-1379.
48. Weier K, Fluri F, Kos S, Gass A. Postcontrast FLAIR MRI demonstrates blood-brain barrier dysfunction in pres. Neurology. 2009;72:760-762.
49. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13:1029-1031. (Pubitemid 47517512)
50. Weiner HL, Frenkel D. Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol. 2006;6:404-416.
51. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-A beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2001;98:8850-8855. (Pubitemid 32678116)
52. Greenberg SM, Frosch MP. Life imitates art: Anti-amyloid antibodies and inflammatory cerebral amyloid angiopathy. Neurology. 2011;76: 772-773.
53. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, et al. MDR1-p-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007;17:347-353. (Pubitemid 47537591)
54. Loeb MB, Molloy DW, Smieja M, Standish T, Goldsmith CH, Mahony J, et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. J Am Geriatr Soc. 2004;52:381-387. (Pubitemid 38339518)